1. ALLA AKTIER
  2. NYHETER
  3. LIDDS

LIDDS

Nyheter LIDDS Nyheter alla bolag

LIDDS’ Annual Report 2024 published

MARKN.

GOTHENBURG, SWEDEN – The 2024 Annual report of LIDDS AB (publ) is now available on the company website.

The annual report is available in Swedish in PDF format on the company website at: https://liddspharma.com/en/investors/financial-reports/.

Copies can be ordered from LIDDS AB, co Excore, Kungsportsavenyen 22, 411 36 Göteborg or by e-mail: info@liddspharma.com.

For additional information, please contact

Mats Wiking, CEO and CFO
Phone: +46 (0)70 620 04 00
E-mail: mats.wiking@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

Attachments

Årsredovisning 2024 LIDDS AB (publ)
Revisionsberättelse 2024 LIDDS AB (publ)

Datum 2025-05-06, kl 08:00
Källa MFN
Bifogade filer
Årsredovisning 2024 LIDDS AB (publ)
Revisionsberättelse 2024 LIDDS AB (publ)
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.